Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lindsey Winfield

Nurse Practitioner Louisville, KY Nurse Practitioner

NPI 1366825523 CMS profile 10680285

1607 Dixie Hwy, Louisville, KY 40210

Open in the dashboard

General payments

$7,521

482 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsey Winfield of Louisville, KY is reported in the CMS Open Payments database as having received $7,521 across 482 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,304 135
2024 General $1,924 133
2023 General $1,667 100
2022 General $1,163 83
2021 General $463 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsey Winfield
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lindsey Winfield were reported at $2,304. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lindsey Winfield Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $463 $135 $40–$426 $132
2022 $1,163 $152 $48–$470 $149
2023 $1,667 $166 $54–$529 $160
2024 $1,924 $173 $55–$556 $164
2025 $2,304 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,983 126 payments
  2. Novo Nordisk Inc $1,207 80 payments
  3. Pfizer Inc. $894 61 payments
  4. Lilly USA, LLC $538 36 payments
  5. GlaxoSmithKline, LLC. $475 36 payments
  6. Amgen Inc. $391 28 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $374 26 payments
  8. ITI, Inc. $179 9 payments
  9. Medtronic, Inc. $171 1 payment
  10. Otsuka America Pharmaceutical, Inc. $159 8 payments
  11. Other $1,149 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,521 482 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $922 64 payments
  2. Ozempic $669 45 payments
  3. UBRELVY $642 34 payments
  4. QULIPTA $623 33 payments
  5. RYBELSUS $589 40 payments
  6. MOUNJARO $444 28 payments
  7. NURTEC ODT $398 41 payments
  8. TRELEGY ELLIPTA $386 30 payments
  9. Wegovy $371 23 payments
  10. Repatha $346 25 payments
  11. Other $5,153 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

4,994

Median for Nurse Practitioner: 389

Drug cost

$459,852

Median for Nurse Practitioner: $21,885

Branded share of claims

17.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 50 $81,510
Jardiance Empagliflozin Brand 43 $63,402
Eliquis Apixaban Brand 57 $61,497
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 51 $51,219
Januvia Sitagliptin Phosphate Brand 41 $50,861
Xarelto Rivaroxaban Brand 16 $25,423
Farxiga Dapagliflozin Propanediol Brand 18 $16,089
Repatha Sureclick Evolocumab Brand 25 $14,672
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 15 $11,844
Brilinta Ticagrelor Brand 18 $10,924

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$38,365

Of which drugs: $4,906

Medicare patients

159

Average age 72

Services billed

897

89 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Diabetes 25%
Ischemic heart disease 19%
Atrial fibrillation 16%
COPD 15%
Cancer 14%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 24 24 $1,800

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $348
$348 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $136
$136 51 —
MOUNJARO
  • Lilly USA, LLC $133
$133 — —
QULIPTA
  • AbbVie, Inc. $107
$107 — —
Repatha
  • Amgen Inc. $105
$105 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record